Table 2 Measures of agreement between selected OCR-based and POGONIS-based diagnostic subgroups
Malignancy type | N, POGONIS | N, OCR | Kappa (95 % CI) | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|---|
Ia.1. Precursor cell leukemias (acute lymphoblastic leukemia) | 1070 | 775 | 0.77 (0.75–0.80) | 0.71 | 0.99 | 0.98 | 0.91 |
Ib. Acute myeloid leukemias | 187 | 164 | 0.84 (0.81–0.89) | 0.80 | 1.00 | 0.91 | 0.99 |
IIa. Hodgkin lymphomas | 312 | 310 | 0.99 (0.98–1.00) | 0.98 | 1.00 | 0.99 | 1.00 |
IIb-IId, IIe. Non Hodgkin lymphomas | 271 | 244 | 0.78 (0.74–0.82) | 0.76 | 0.99 | 0.84 | 0.98 |
IIb.1 Precursor cell lymphomas (lymphoblastic lymphomas) | 67 | 22 | 0.24 (0.12–0.36) | 0.16 | 1.00 | 0.50 | 0.99 |
IIc. Burkitt lymphomas | 78 | 1 | 0.02 (0.02–0.07) | 0.01 | 1.00 | 1.00 | 0.98 |
IIIb. Astrocytomas | 446 | 343 | 0.82 (0.79–0.85) | 0.74 | 1.00 | 0.96 | 0.97 |
IIIa1. Ependymomas | 72 | 69 | 0.95 (0.91–0.99) | 0.93 | 1.00 | 0.97 | 1.00 |
IIIc. Intracranial and intraspinal embryonal tumors | 199 | 201 | 0.91 (0.87–0.94) | 0.91 | 1.00 | 0.91 | 1.00 |
IIIc.1 Medulloblastomas | 152 | 134 | 0.91 (0.88–0.95) | 0.86 | 1.00 | 0.98 | 1.00 |
IIIx. All other CNS tumors | 73 | 144 | 0.34 (0.26–0.43) | 0.53 | 0.97 | 0.27 | 0.99 |
IVa. Neuroblastoma and ganglioneurblastoma | 259 | 254 | 0.97 (0.96–0.99) | 0.97 | 1.00 | 0.98 | 1.00 |
VIa.1 Nephroblastoma | 141 | 140 | 0.98 (0.97–1.00) | 0.98 | 1.00 | 0.99 | 1.00 |
VIIa. Hepatoblastoma | 58 | 56 | 0.96 (0.93–1.00) | 0.95 | 1.00 | 0.98 | 1.00 |
VIIIa. Osteosarcoma | 88 | 87 | 0.96 (0.93–0.99) | 0.95 | 1.00 | 0.97 | 1.00 |
VIIIc. Ewing tumor and related sarcomas of bone | 82 | 93 | 0.81 (0.74–0.87) | 0.87 | 0.99 | 0.76 | 1.00 |
IXa. Rhabdomyosarcomas | 116 | 128 | 0.92 (0.89–0.96) | 0.97 | 1.00 | 0.88 | 1.00 |
IXb-IXe. Non-rhabdomyosarcoma soft tissue sarcomas | 153 | 132 | 0.71 (0.65–0.77) | 0.67 | 0.99 | 0.78 | 0.99 |